Lanthanum carbonate (Shire).
IDrugs
; 6(7): 688-95, 2003 Jul.
Article
en En
| MEDLINE
| ID: mdl-12861474
ABSTRACT
Shire Pharmaceuticals Group plc, under exclusive license from AnorMED Inc (a subsidiary of Johnson Matthey), is developing lanthanum carbonate, a phosphate-binding lanthanum salt, for the potential treatment of hyperphosphatemia in dialysis patients. It is currently in pre-registration in the US, Canada and Western Europe, and earlier stage clinical trials are ongoing in Japan.
Buscar en Google
Base de datos:
MEDLINE
Asunto principal:
Insuficiencia Renal
/
Lantano
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
En
Revista:
IDrugs
Asunto de la revista:
FARMACOLOGIA
Año:
2003
Tipo del documento:
Article
País de afiliación:
Italia